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Summary Ki-ras activation by point mutation on codon 12 has been reported in non-small-cell lung
carcinomas and in various models of experimental lung tumours induced by chemical carcinogens. The cellular
targets for carcinogenic compounds of tobacco smoke are usually considered to be the cells of the bronchial
mucosa or alveolar epithelium. However, little is known about preneoplastic events in bronchopulmonary
carcinogenesis. The hypothesis of the presence of widespread target cells containing Ki-ras mutation was
investigated by evaluating concurrent neoplastic and non-neoplastic bronchial and alveolar samples from 51
patients with non-small-cell lung carcinomas. The polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) method used can detect one cell with a mutation on codon 12 among 102 normal
cells. In tumour samples, a mutation was detected in 20% of adenocarcinomas, but in none of the
adenosquamous or squamous cell carcinomas. No mutation was detected in the non-neoplastic bronchial or
parenchymal samples. When using an enriched PCR-RFLP method detecting one mutated allele among 103
normal alleles a mutation was detected in 23% of adenocarcinomas. In conclusion, Ki-ras activation by
mutation on codon 12 was not observed in non-neoplastic bronchial or parenchymal tissues in patients with
bronchopulmonary cancers and does not appear to be a genetic event present in non-malignant epithelial target
cells exposed to tobacco smoke.
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The Ki-ras proto-oncogene has been shown to be activated by
point mutations in a wide variety ofhuman and experimental
carcinomas (Barbacid, 1987; Bos, 1989). Dutch researchers
reported that in lung carcinomas Ki-ras mutations were found
exclusively in adenocarcinomas With a frequency of 30% in
smokersand 5% innon-smokers(Bos, 1989; Slebosetal., 1991).
In neoplastic tissues more than 90% of Ki-ras mutations
occurred in codon 12 (Bos, 1989; Slebos et al., 1991). In
contrast, in another series from Spain, Ki-ras mutations were
not only detected in adenocarcinomas, but the majority ofKi-
rasmutations werepresent in squamouscellcarcinomas (Rosell
etal., 1993). Inexperimentalmodels oflung tumoursconducted
in different mouse strains, various chemical carcinogens have
been demonstrated to induce tumours harbouring a Ki-ras
mutation restricted to codon 12 [You et al., 1989, 1993; Mass et
al., 1993). These human and experimental data suggest that
codon 12 of Ki-ras may be a specific target for the mutagenic
activity of various compounds of tobacco smoke (Husafvel-
Pursiaisen et al., 1993).
In colonic carcinogenesis, Ki-ras mutation has been shown
to be a preneoplastic event (Burmer and Loeb, 1989). In
contrast, little is known about preneoplastic events in
bronchopulmonary carcinogenesis. However, recent reports
demonstrated that Ki-ras and p53 mutations occur very early
in the development of pulmonary adenocarcinomas (Sozzi et
al., 1992; Sundaresan et al., 1992; Benett, 1993; Li et al.,
1994). The cellular targets for the carcinogenic compounds of
tobacco smoke are usually considered to be either the
bronchial mucosa or alveolar epithelium (Carney, 1991).
Therefore, the hypothesis of the presence of widespread
target cells containing Ki-ras mutations in the respiratory
tract as already shown for the suppressor gene p53 has to be
considered (Sozzi et al., 1992; Sundaresan et al., 1992; Benett
1993; Li et al., 1994).
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Consequently, the present study was designed to
investigate the presence of activated Ki-ras by mutation in
codon 12 not only in adenocarcinomas, but also in various
non-small-cell bronchopulmonary cancer tissues and in




Tissue specimens were collected in 68 smokers or ex-smokers
who were patients for thoracotomy undertaken with curative
intent. The resected material was transported to the
pathology department, and after examination by the
pathologist, a representative part of the tumour was snap-
frozen and stored at -70°C until analysis. To increase the
sensitivity of detection, macroscopically neoplastic tissue was
collected under a dissection microscope.
Concomitantly, in 51 patients, non-neoplastic bronchial
and parenchymal specimens were also collected close to and
away from the tumour and snap-frozen at -70°C. Tissue
samples were also embedded in paraffin wax for histological
analysis and classified according to the WHO classification
into squamous cell carcinomas (SCC), adenocarcinomas (AC)
or adenosquamous carcinomas (ASC).
DNA evaluation by polymerase chain reaction (PCR)
amplification and restriction fragment length polymorphism
(RFLP) analysis
A rapid method of extraction of DNA from tissues and cell
cultures was performed according to Higuchi (1989). Ki-ras
codon 12 sequences were amplified according to Jiang et al.
(1989) using a 5'-end primer that contains a C substitution
at the first position of codon 11 creating a BstNI site which
overlaps the first two nucleotides of codon 12. The 3' primer
also contains a substitution creating a control BstNI site.Ki-ras evaluation in tumoral and normal lung tissue
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The primers, synthesized by a DNA synthesiser (Applied
Biosystems) and purified by high performance liquid
chromatography (HPLC) (Genset, Paris), were Ki-ras 5':
5'-ACT GAA TAT AAA CTT GTG GTA GTT GGA
CCT-3' and Ki-ras 3': 5-TCA AAG AAT GGT CCT GGA
CC-3'. DNA was amplified according to Saiki et al. (1988)
using a Perkin-Elmer Cetus thermal cycler. DNA was
denatured at 94°C for 10 min and subsequently amplified
for 40 cycles. The PCR reaction was carried out in 0.1 ml
containing 50 mM potassium chloride, 10 mM Tris-HCl, pH
8.3, 1.5 mM magnesium chloride, 2.0 mM of each dNTP,
with 350 ng of each primer and 2.5 units of Taq DNA
polymerase (Beckman). The reaction mixture was overlayed
with mineral oil. Each cycle included a 1 min denaturation
step at 94°C, a 1 min annealing step at 55°C and a 1.5 min
elongation step at 72°C. PCR reaction product (10 Ml) was
analysed by 2% agarose gel electrophoresis. Specimens with
negative results were re-evaluated in a second separate PCR
amplification. Aliquots (20 ul) of the PCR reaction product
were then digested with the restriction enzyme Bst,/it>NI
(Boehringer Mannheim, France) at 37°C for 2 h and
electrophoresed through an 8% polyacrylamide gel. The
results were analysed after ethidium bromide staining and
UV transillumination.
Codon 12 mutation identification by specific oligonucleotide
hybridisation
Ten samples (six wild-type and four mutated codon 12 of c-
K-ras genes) were studied by specific oligonucleotide
hybridisation. After extraction, the DNA was heat dena-
tured and used for in vitro amplification. The PCR procedure,
oligonucleotide sequences, hybridisation conditions in ammo-
nium tetramethylchloride and composition of the seven
probes used have been described previously by Verlaan de
Vries et al. (1986).
Enriched PCR/RFLP analysis
An enriched PCR/RFLP method derived from Kahn et al.
(1991) was concurrently performed in non-tumoral and
tumoral samples from lungs of 32 patients with adenocarci-
nomas. Ki-ras codon 12 sequences were amplified in two
steps. Primers used were K-ras 5' (as described above), K-ras
3' wild type (5'-TCA AAG AAT GGT CCT GCA CC-3') and
K-ras 3' (as described above).
First step amplification The PCR reaction was carried out in
0.1 ml containing 50 mM potassium chloride, 10 mM Tris-
HCl, pH 8.3, 1.5 mM magnesium chloride, 0.2 mM dNTPs
and 2.5 units of Taq DNA polymerase (Beckman). Primer
concentrations were 10 ng each of K-ras 5' and Ki-ras 3'
wild-type. The reaction mixture was overlayed with mineral
oil. Each cycle included a 1 min denaturation step at 940C, a
1 min 30 s annealing step at 56°C and a 2 min elongation
step at 72°C, for a total of 15 cycles.
Intermediate digestion Aliquots (5 jul) of the first PCR
reaction were digested with 20 units of the restriction
enzyme BstNI (Boehringer Mannheim, France) in a final
volume of 10 pl at 37°C for 3 h under conditions
recommended by the supplier.
Second step amplification Digested mixture (10 pl) was used
in the second amplification step. These aliquots were diluted
to a final volume of 50 pl as described above. Primer
concentrations were 100 ng each of Ki-ras 5' and Ki-ras 3',
and amplification was performed for 30 cycles as above.
RFLP analysis Aliquots (20 pl) of the products obtained
after the second step were digested with the restriction
enzyme BstNI (10 units) at 37°C for 2 h in a final volume of
30 pl. The results were analysed after ethidium bromide
staining and UV transillumination.
Control cell lines
SW480 (homozygous for a mutated Ki-ras gene codon 12,
valine, GTT) and HT29 (homozygous for the wild-type Ki-
ras gene codon 12, glycine, GGT) human colon carcinoma
cell lines were obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA). All were grown in
the prescribed media.
Results
One-step PCR amplification and RFLP analysis
Amplification of Ki-ras codon 12 sequence gave a 157 bp
fragment. Digestion of wild-type codon 12 sequence with
Bst NI generated a 114 bp fragment, while, when a mutation
was present in codon 12, BstNI digestion generated a 143 bp
fragment, as shown in Figure 1. Therefore, the presence of a
143 bp fragment after digestion is the hallmark of the
presence of mutated Ki-ras genes on codon 12.
Detection of codon 12 c-Ki-ras mutation in SW480 and HT29
cell lines
Two human cell lines with documented codon 12 Ki-ras gene
were examined to validate the method. SW480 is derived
from a human colon carcinoma and is a homozygous mutant
(GGT to GTT) (Capon et al., 1983). HT29 is also derived
from a human colon carcinoma and has homozygous wild-
type alleles (codon 12 Ki-ras, GGT). PCR amplification and
BstNI RFLP analysis of DNA from the SW 480 cell line
showed only a 143 bp fragment confirming the homozygous
mutation. Analysis of DNA from the HT29 cell line showed
a wild-type 114 bp fragment. Analysis of a mixture of DNA
from the two cell lines showed two fragments of 143 and
114 bp respectively. The sensitivity of the assay was therefore
tested by a series of titration experiments. The threshold of
detection was one cell with a homozygous mutation in the
midst of 102 cells with a wild-type Ki-ras gene (Figure 2)
(Urban et al., 1993).
Figure 1 Photograph of DNA electrophoresis through an 8%
polyacrylamide gel after ethidium bromide staining and UV
analysis. Left lane molecular weight markers. The basepair
number is indicated in the right margin. Lanes 1 -2, BstNI
digestion of PCR product after amplification of DNA from
SW480 cell line with homozygous mutation showing a single
143bp fragment. Lanes 3-4, BstNI digestion of PCR product
after amplification of DNA from wild-type HT29 cell line
showing a single 114bp fragment. Lanes 5 and 6, BstNI
digestion of PCR product after amplification of DNA from
samples with heterozygous mutation, showing 114 and 143bp
fragments. Lane 7, Non-digested PCR product showing a 157bp
fragment.Ki-ras evaluation in tumoral and normal lung tissue
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Figure 2 Sensitivity of one-step PCR amplification and RFLP
analysis. Photograph of DNA electrophoresis through an 8%
polyacrylamide gel after ethidium bromide staining and UV
analysis. Left and right lanes, molecular weight markers. The
basepair number is indicated in the right margin. Lane 1, BstNI
digestion of PCR product after amplification of DNA from wild-
type HT29 cell line showing a single 114bp fragment. Lanes 2-6,
BstNI digestion of PCR product after amplification of a mixture
of DNA from HT29 and SW480 cell lines, with the following
SW480/HT29 DNA ratio: lane 2, 1/10000; lane 3, 1/1000; lane 4,
1/100; lane 5, 1/10; lane 6, 1/1. The 114bp fragment is generated
from HT29-Ki-ras gene. In contrast the 143bp fragments
indicated the presence of a SW480 Ki-ras gene mutated on
codon 12. The sensitivity ratio was 1/100. Lane 7, BstNI digestion
of PCR product after amplification of DNA from SW480 cell line
with homozygous mutation showing a single 143bp fragment.
When using the enriched PCR-RFLP method (Kahn et
al., 1991), the threshold of detection was one cell with
homozygous mutation in the midst of 103 cells with a wild-
type Ki-ras gene (Figure 3).
Detection of codon 12 c-Ki-ras mutation in patient samples
The results of the DNA evaluation by PCR amplification and
RFLP analysis (PCR-RFLP method) are shown in Tables I
and II.
When using the one step PCR-RFLP method no
mutation involving the codon 12 of Ki-ras gene was detected
in the 20 squamous cell and four adenosquamous cell
carcinomas. In contrast a mutation was detected in 9/44
(20.5%) of the adenocarcinomas. When using the enriched
PCR-RFLP method, a mutation was detected in 10/44
(23%) of the adenocarcinomas.
As a control of the method, ten samples were studied by
specific oligonucleotide hybridisation. No mutation was
detected in the six samples found to be of the wild type by
PCR-RFLP analysis. In contrast, the four samples in which
a mutated codon 12 of Ki-ras was detected by PCR-RFLP
analysis, the mutation could be specific (2:GGT-+GTT;
1:GGT-+GCT;1:GGT-+TGT).
No mutation of the codon 12 of Ki-ras gene was detected
in the non-neoplastic bronchial and parenchymal specimens
even in the samples from lungs with adenocarcinomas
harbouring a Ki-ras mutation (Table II).
Figure 3 Sensitivity of 'enriched' PCR amplification and RFLP
analysis. Photograph of DNA electrophoresis through an 8%
polyacrylamide gel after ethidium bromide staining and UV
analysis. Left and right lanes, molecular weight markers. The
basepair number is indicated in the right margin. Lane 1, BstNI
digestion ofPCR product after amplification of DNA from HT29
cell line showing a single 114bp fragment. Lanes 2-3, BstNI
digestion of PCR product after amplification of a mixture of
DNA from HT29 and SW480 cell lines, with the following
SW480/HT29 DNA ratio: lane 2, 1/100000; lane 3, 1/10000. The
114bp fragment is generated from HT29-Ki-ras gene. The 143bp
fragment is not detected. Lane 4-7, BstNI digestion of PCR
product after amplification of a mixture of DNA from HT29 and
SW480 cell lines, with the following SW480/HT29 DNA ratio:
lane 4, 1/1000; lane 5, 1/100, lane 6, 1/10; lane 7, 1/1. The 114bp
fragrnent is generated from HT29-Ki-ras gene. In contrast the
143bp fragments indicated the presence of a SW480 Ki-ras gene
mutated on codon 12. The sensitivity ratio is 1/1000. Lane 8
BstNi digestion of PCR product after amplification ofDNA from
SW480 cell line showing a single 143bp fragment.
Table I Detection of a codon 12 Ki-ras mutation by one-step
PCR-RLFP method in 68 malignant and 51 non-neoplastic tissues
from patients with non-small-cell lung carcinoma
Malignant tissue Non-neoplastic tissue
Mutated Mutated
n Ki-ras n Ki-ras
Adenocarcinomas 44 9 32 0
Squamous cell 20 0 15 0
carcinomas
Adenosquamous 4 0 4 0
cell carcinomas
Table II Presence of ki-ras mutations in lung adenocarcinomas and
apparently normal tissues evaluated by one-step PCR-RFLP and
enriched PCR-RFLP methods
Mutated Ki-ras
n One-step PCR Enriched PCR
Adenocarcinomas 44 9 10
Concurrent samples 32
Malignant tissue 4 5
Non-neoplastic 0 0
tissuea
aApparently normal bronchial and lung tissue.
Discussion
The methods chosen for the detection of a mutation in codon
12 of the Ki-ras gene were a combination of PCR
amplification of DNA and RFLP analysis (Jiang et al.,
1989). These methods offer several advantages. They are
highly specific, as the loss of the restriction site at the target
is diagnostic for the presence of a mutation. An additional
restriction site offers a control of the restriction enzyme
digestion. In the present study the one-step PCR-RFLP
analysis was shown to be able to detect a K-ras mutation
when it is present in 1% of cells studied. When using the
enriched PCR-RFLP procedure, one mutated allele could be
detected among 103 normal alleles.
In the present series of 68 non-small-cell lung carcinomas,
activation of Ki-ras by a mutation on codon 12 was observed
in ten of the 44 adenocarcinomas. Such a frequency (23%) is
in agreement with most ofthe previous reports (Rodenhuis et
al., 1988; Slebos et al., 1990). No mutation was detected inKi-ras evaluation in tumoral and normal lung dssue
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the 20 squamous and four adenosquamous cell carcinomas
investigated. This result is in line with most of the reports
which demonstrated that Ki-ras mutations were restricted to
adenocarcinomas except for Rosell et al. (1993), who
observed Ki-ras mutations in squamous cell carcinomas. In
this last series, mutations were also detected in codon 61
which was not investigated in the present study, focusing on
codon 12 of Ki-ras.
In experimental models of lung tumours induced in
various murine strains, the presence of Ki-ras mutation is a
particularly reproducible event. For example, in the strain A
mouse highly susceptible to spontaneous and inducible lung
tumours, Ki-ras point mutations in spontaneous lung
tumours were found in both codons 12 (60%) and 61
(30%) (You et al., 1989, 1993; Mass et al., 1993). After
tumour induction in this mouse strain, the pattern of Ki-ras
mutation was different according to the carcinogen used: in
codon 12 for 100% of tumours after induction by methyl
nitrosourea and 93% after benzo[a]pyrene exposure, in
contrast, 90% of the mutations after ethyl carbonate
exposure were situated in codon 61 (You et al., 1989).
Benzo[a]pyrene is considered to be a major carcinogenic
compound of tobacco smoke (Loeb et al., 1984). In human
lung and pancreatic adenocarcinomas, the presence of codon
12 Ki-ras mutation has been shown to be related to tobacco
smoke exposure (Hruban et al., 1993; Westra et al., 1993).
Ras activation by mutation, particularly Ki-ras, has been
shown to be present in a wide variety of human neoplasms
(Bos, 1989). Moreover, it has been suggested that Ki-ras
oncogene activation could precede the onset of neoplasia
(Kumar et al., 1990). For colonic carcinoma, Ki-ras
activation by mutation was observed in adenomas before
the development of non-invasive cancer and is therefore
under investigation for the survey of at-risk patients
(Sidransky et al., 1992). Moreover, when using an enriched
PCR method, Ki-ras mutations could be detected in normal
colonic mucosa at a distance from the tumour (Ronai et al.,
1994; Minamoto et al., 1995). For pancreatic carcinomas, Ki-
ras mutations have been detected in mucous hyperplasia
associated with pancreatitis, suggesting they may be
precancerous epithelial modifications (Yanagisawa et al.,
1993). For lung adenocarcinomas, c-Ki-ras mutations occur
early since they have been detected in all stages of lung
cancer (Li et al., 1994). Moreover, these mutations are
considered to be an irreversible event (Westra et al., 1993).
Widespread dysplastic lesions have been observed in
bronchi of cigarette smokers increasing in a dose-dependent
manner according to the number of cigarettes smoked
(Auerbach et al., 1979). Multiple mutations are necessary
for the transformation of epithelial cells and the exact order
in which they are acquired is difficult to ascertain.
p53 mutations present in both squamous cell carcinomas
and adenocarcinomas have been detected in association with
lesions considered to be precancerous such as bronchial
squamous metaplasia or dysplastic tissue (Sozzi et al. 1992;
Sundaresan et al., 1992; Benett, 1993; Li et al., 1994). Similar
results were reported for the loss of 3p allele observed in
most bronchopulmonary carcinomas (Brauch et al., 1987).
In contrast, in our series, as for the patient investigated by
Santos et al. (1984), no Ki-ras mutations in codon 12 were
detected in bronchial and lung parenchymal samples from
patients with non-small-cell lung carcinomas, even when
mutations were present in tumour samples. Moreover, no Ki-
ras mutation was detected in dysplastic bronchial epithelium
associated with lung adenocarcinomas (Li et al., 1994).
However, rare cells with mutations below the threshold of
detection may be present.
Clements et al. (1995) recently reported Ki-ras mutation in
non-malignant bronchial tissue in patients with lung
carcinomas. Such a discrepancy can be explained by the
fact that Clements et al. evaluated samples from the carina of
proximal bronchi. In contrast, we deliberately studied
peripheral bronchial or alveolar lung tissue as they are
suspected to be possible cellular targets for carcinogens in
adenocarcinomas. Bronchial carina has been shown to be the
site of epithelial changes in response to constant exposure to
airborne contaminants (Knudtson et al., 1960). However, it is
not suspected to be the site of occurrence of adenocarcino-
mas.
In conclusion, Ki-ras mutations were detected in proximal
bronchial carina in another study. In the present study, Ki-
ras mutations were not detected in peripheral bronchial and
lung parenchyma associated with lung tumours, particularly
adenocarcinomas. These results suggest that these mutations
do no occur in widespread cellular genomes induced by
tobacco smoke in peripheral bronchial and lung tissue.
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